Clinical evaluation of squamous cell carcinoma antigen in squamous cell carcinoma arising in mature cystic teratoma of the ovary.
Clinical evaluation of squamous cell carcinoma antigen in squamous cell carcinoma arising in mature cystic teratoma of the ovary.
复制标题
卵巢成熟囊性畸胎瘤产生的鳞状细胞癌中鳞状细胞癌抗原的临床评价。
作者：
M. Suzuki;H. Kobayashi;I. Sekiguchi;K. Konnai;T. Terao;I. Sato
我们试图评估鳞状细胞癌抗原（SCC）检测卵巢成熟囊性畸胎瘤中鳞状细胞癌的临床应用价值。用放射免疫法测定了16例恶性囊性畸胎瘤和56例非恶性成熟囊性畸胎瘤患者血清SCC。16例恶性肿瘤患者中有9例（56%）血清SCC水平超过2.0 ng/ml的临界值。与非恶性成熟性囊性畸胎瘤比较，差异有显著性意义（9 ~ 56，16%; P < 0.01）。SCC的阳性率在I期癌中低至30%。所有肿瘤大小> 500 cm 3的病例对SCC均呈阳性反应，而所有其他病例均呈阴性反应（p < 0.001）。SCC可作为这种恶性肿瘤的肿瘤标志物。然而，血清SCC水平取决于肿瘤体积，因此可能不适合早期发现小肿瘤。
We attempted to assess the clinical utility of squamous cell carcinoma antigen (SCC) for detecting squamous cell carcinoma arising in mature cystic teratoma of the ovary. SCC in serum from 16 patients with this malignancy and from 56 patients with mature cystic teratoma without malignancy was measured using radioimmunoassay. Serum SCC levels exceeded the cut-off of 2.0 ng/ml in 9 (56%) of the 16 patients with malignancy. This rate was significantly higher than that in the patients with nonmalignant mature cystic teratoma (9 to 56, 16%; p < 0.01). The positive rate for SCC was as low as 30% for stage I cancer. All cases in which the tumor size was > 500 cm3 had a positive response for SCC, whereas all other cases had a negative response (p < 0.001). SCC is useful as a tumor marker for this malignancy. However, the serum SCC level depends on the tumor volume, so it may not be suitable for early detection of small tumors.